ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBPBiotechnology
+$0.44 today
- Market cap
- $563.78M
- Beta
- 1.42
- P/E (TTM)
- -9.8
- EPS (TTM)
- -$3.22
Volume 2.70M
Average 0.50M
AVBP Total Non-current Assets
All assets not expected to be converted to cash within one year.
ArriVent BioPharma, Inc. Common StockNASDAQ: AVBP
Total Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Total non-current assets falls 98.0% from a year ago
Total non-current assets stood at $595K at the end of Q1 FY2026, down 98.0% from a year earlier and up 118.8% from the prior quarter. Over 3 fiscal years it compounded at +8.8% a year.
Context
- Total non-current assets amounted to 0.2% of total assets at the end of Q1 FY2026, down 13.6 pp from a year earlier.
- Total non-current assets increased in 2 of the last 3 fiscal years.
What to watch
Whether total non-current assets keeps falling in the next quarterly balance sheet after a -98.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 272K USD
- Year-over-year change
- -99.4%
- 4-year CAGR
- +33.0%
| Period | Period end | Total Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 272K | -99.4% |
| FY2024 | 2024-12-31 | 47.96M | +1432.4% |
| FY2023 | 2023-12-31 | 3.13M | +1383.4% |
| FY2022 | 2022-12-31 | 211K | +142.5% |
| FY2021 | 2021-12-31 | 87K | — |
Total Non-current Assets vs competitors
How AVBP compares with its peers on the latest reported figures
- AVBP's Mar 2026 total non-current assets of $595K is the lowest of the 11 companies compared; the peer median is $153.64M.
- Its year-over-year change of -98.0% is the lowest of 11, against a peer median of -12.7%.
- Total non-current assets amounts to 0.2% of total assets for AVBP, versus a peer median of 20.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jul 2026 | $1.24B | -17.0% | -1.2% | 49.9% | |
| Sep 2026 | $343.74M | +185.3% | +16.0% | 34.4% | |
| Mar 2026 | $334.24M | -14.9% | +193.4% | 32.4% | |
| Dec 2025 | $185.76M | -10.5% | -0.7% | 10.6% | |
| Jun 2026 | $160.76M | +23.6% | +16.9% | 15.0% | |
| Mar 2026 | $146.53M | +366.3% | +45.4% | 33.5% | |
| Mar 2026 | $50.44M | -20.8% | -15.2% | 26.2% | |
| Jun 2026 | $18.07M | -24.8% | +69.1% | 2.4% | |
| Mar 2026 | $17.43M | -7.8% | +24.5% | 4.2% | |
| Mar 2026 | $9.96M | -51.6% | -28.2% | 7.5% | |
| Mar 2026 | $595K | -98.0% | +8.8% | 0.2% | |
| Peer median (excluding AVBP) | $153.64M | -12.7% | +16.5% | 20.6% | |
Competitors are the stored peer set for AVBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 37.28M | 163.37M | 150.39M | 74.29M | 45.54M |
| Short-term Investments | 0 | 0 | 0 | 144.57M | 267.28M |
| Net Receivables | 0 | 0 | 0 | 500K | 60K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 5.64M | 18.92M | 9.21M | 7.21M | 20.02M |
| Total Current Assets | 42.95M | 182.62M | 159.97M | 226.98M | 332.9M |
| Property, Plant & Equipment (Net) | 0 | 139K | 291K | 154K | 13K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 47.68M | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 87K | 72K | 2.84M | 126K | 259K |
| Total Non-current Assets | 87K | 211K | 3.13M | 47.96M | 272K |
| Total Assets | 43.04M | 182.83M | 163.1M | 274.94M | 333.17M |
| Account Payables | 293K | 3.09M | 4.53M | 3.78M | 5.93M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 4.16M | 6.55M |
| Total Current Liabilities | 1.82M | 8.36M | 11.62M | 17.27M | 25.95M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 0 | 11K | 177K | 14K | 0 |
| Total Liabilities | 1.82M | 8.37M | 11.8M | 17.29M | 25.95M |
| Common Stock | 0 | 0 | 0 | 3K | 4K |
| Retained Earnings | (51.61M) | (88.51M) | (157.85M) | (238.33M) | (404.64M) |
| Accumulated OCI | (2K) | 0 | 0 | (211K) | 14K |
| Other Stockholders Equity | (0) | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 41.22M | 174.46M | 151.3M | 257.65M | 307.22M |
| Total Debt | 0 | 139K | 317K | 176K | 14K |
| Net Debt | (37.28M) | (163.23M) | (150.07M) | (74.12M) | (45.53M) |
ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBP
Intrinsic Alpha fair value
Locked
Current Price
$10.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.